Lupus nephritis
Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe
organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE). Most …
organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE). Most …
Novel paradigms in systemic lupus erythematosus
The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is
now challenging the entire lupus community, from geneticists to clinical investigators …
now challenging the entire lupus community, from geneticists to clinical investigators …
Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …
L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study
Background: Patients with chronic inflammatory disease (CID) treated with
immunosuppressive medications have increased risk for severe COVID-19. Although mRNA …
immunosuppressive medications have increased risk for severe COVID-19. Although mRNA …
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …
[HTML][HTML] Two-year, randomized, controlled trial of belimumab in lupus nephritis
R Furie, BH Rovin, F Houssiau, A Malvar… - … England Journal of …, 2020 - Mass Medical Soc
Background In adults with active lupus nephritis, the efficacy and safety of intravenous
belimumab as compared with placebo, when added to standard therapy (mycophenolate …
belimumab as compared with placebo, when added to standard therapy (mycophenolate …
Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
A Padmanabhan, L Connelly‐Smith… - Journal of clinical …, 2019 - Wiley Online Library
ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Systemic lupus erythematosus: diagnosis and clinical management
A Fava, M Petri - Journal of autoimmunity, 2019 - Elsevier
Systemic lupus erythematosus (SLE) is a worldwide chronic autoimmune disease which
may affect every organ and tissue. Genetic predisposition, environmental triggers, and the …
may affect every organ and tissue. Genetic predisposition, environmental triggers, and the …
Management strategies and future directions for systemic lupus erythematosus in adults
L Durcan, T O'Dwyer, M Petri - The Lancet, 2019 - thelancet.com
Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by the loss of
self-tolerance and formation of nuclear autoantigens and immune complexes resulting in …
self-tolerance and formation of nuclear autoantigens and immune complexes resulting in …
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
A Dima, C Jurcut, F Chasset… - Therapeutic …, 2022 - journals.sagepub.com
The antimalarial hydroxychloroquine (HCQ) has demonstrated several crucial properties for
the treatment of systemic lupus erythematosus (SLE). Herein, we reviewed the main HCQ …
the treatment of systemic lupus erythematosus (SLE). Herein, we reviewed the main HCQ …